Login to Your Account



Clinic Roundup


Wednesday, February 29, 2012
• Tau Therapeutics LLC, of Charlottesville, Va., said the FDA accepted its investigational new drug application for T-type calcium channel blocker mibefradil, and the firm anticipates launching a Phase I trial in healthy volunteers March 2. Mibefradil is a compound that has been used in hypertension before Tau repositioned it for oncology indications.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription